How Biomarkers Can Be Used In The Battle Against Ovarian Cancer

Over 19 million new cases of cancer were report worldwide in 2020.1For women * , one of the most common type of cancer is ovarian genus Cancer , with more than 310,000 the great unwashed being diagnose with the disease worldwide each year.1Like most cancer types,2age is a risk of exposure factor for ovarian cancer , but it can affect younger people too.3

While endurance rates for ovarian cancer have reassuringly ameliorate in recent years,4the survival charge per unit of ovarian cancer is still comparatively poor compared to other gynaecologic cancers.5,6,7One of the main understanding is because ovarian cancer is hard to spot in the other stage and symptoms are nonspecific , meaning it can often go unnoticed.8If a speedy diagnosing is n’t reached , the Cancer the Crab may be more advanced and harder to manage.9,10The on-going COVID-19 pandemic has also put a vast line on health care systems , leading to few patients seeing their doctors in certain parts of the world,11further causing time lag to ovarian genus Cancer diagnoses.12

No two people are the same and no two Cancer are the same . Each individual cancer is unique and possesses different biological characteristics.13A individualized approach using unlike exam and diagnostics is need to find the best direction to conduct with each person ’s cancer.14This is why biomarkers can be so important.15

What Are Biomarkers?

Biomarkers are measurable indicators of some variety of biological state or activeness in your body.16Examples of biomarkers include specific jail cell , molecules , genes , enzymes , or hormones whose presence can point a disease or infection , and its severity , as well as your endangerment of developing a disease.17,18In Crab guardianship , the presence of a biomarker can be a clew that doctors can utilise to understand if a person is at higher risk of developing cancer , if they have cancer , and if so , its risk of progression.15,19

Since each individual cancer is unique , not all people respond to Crab direction in the same way.20To get a better intellect of a person ’s Cancer the Crab , physician can carry out a biomarker test , also referred to as a “ molecular test ” or “ genomic tryout ” to determine the presence of biomarkers in their blood , other body fluid , or tissue.15

Doctors can use the presence of certain biomarkers to gain an apprehension of citizenry ’s transmissible difference and their Cancer . This knowledge can help doctor cut guardianship plans for each specific patient.15

Biomarkers and Ovarian Cancer

The Homologous Recombination Repair ( HRR ) pathway is the physical process through which protein repair damaged DNA inside a electric cell , and changes to the pathway can extend to disease admit cancer.21As such , genes involved in the HRR pathway have been identified as actionable biomarkers in cancer research and their presence can assist doctors to tailor care plans.15

In ovarian Crab , there are several genetic biomarkers associated with a faulty HRR pathway including BRCA ( BReast CAncer cistron ) , ATM ( Ataxia telangiectasia mutate ) , BARD1 ( BRCA1 Associated RING Domain 1 ) , and BRIP1 ( BRCA1 Interacting Protein 1).22Any one of these can be a genic discrepancy present in tumours and as such make them indicators of disease for doctors to screen for.22

The BRCA factor may be a aim for sieve as sure mutations can increase a person ’s endangerment of developing ovarian cancer.23This is because the BRCA gene encodes proteins that help repair damaged DNA.23If a somebody is positivist for a BRCA mutation , this may help direct doctors towards a cancer charge plan for that patient.24

Another example of a biomarker used in the management of ovarian cancer is CA125 ( cancer antigen 125).25CA125 is a protein that can be obtain on the surface of ovarian Crab cells , as well as some normal tissues.26A profligate run that appraise the amount of CA125 in the bloodstream can be used to label how alive the tumor is and check for cancer recurrence.27

The CA125 test can be used to block out for ovarian cancer , which has the potentiality to improve event in many lives.28However , the test is far from fool trial impression as many non - cancerous conditions may also raise the point of CA125 in the blood.27As such , a CA125 run is n’t accurate enough to be used for ovarian cancer screening in general and has n’t been read to ameliorate the outcome for those with ovarian cancer but is often used to see how the tumour is respond post - treatment.27

doctor can also screen for the Human Epididymis Protein 4 ( HE4 ) biomarker , a protein that is produced by most , but not all , epithelial ovarian cancer cells.29HE4 can also be tested for in combining with CA125 to improve the sensitivity and specificity of ovarian genus Cancer diagnosis.30

In 2009 , the US Food and Drug Administration ( FDA ) approved OVA1 as another biomarker ancestry test that evaluates blood serum compactness of five marking : CA125 II , β - microglobulin , apolipoprotein A1 , prealbumin , and transferrin.31CA125 and β - microglobulin are upregulated ( they can be found at higher levels ) in ovarian cancer , whereas apolipoprotein A1 , prealbumin , and transferrin are downregulated ( they can be establish at lower levels ) , make OVA1 an effective screening tool . This signify doctors can habituate this test to distinguish patients with a positive resultant role and refer them for further investigation.31

After gathering insights from the biomarker tests , medico will decide the good course of action to take . Their finding can help them to decide upon the good route for care or weigh up management selection to ease symptoms and control progress for as long as possible.15,32

There are a telephone number of options available , including chemotherapy , where medicine is used to wipe out genus Cancer cadre , and surgery to remove the Cancer the Crab tissue.33Some have chemotherapy on its own or combined with surgery.34Other option let in endocrine therapy , which strip ovarian malignant neoplastic disease cell of the endocrine they need to grow , and irradiation , where radiation is used to take out Crab cells or keep them from growing.35

The Future of Ovarian Cancer Biomarker Testing

Scientists are constantly looking for young potential biomarkers for the diagnosis and management of ovarian Crab . One particularly exciting avenue of research is using hokey intelligence information ( AI ) and biomarkers to identify those most at risk of sure cancers . By tight take care at microscopical range of a function of tumours , AI can pick up on patterns not seen by other methods and potentially note new biomarkers.36,37

Fortunately , survival rates for ovarian cancer have importantly improved in recent decades.4,38,39Although , as mention , outcomes for ovarian cancer remain relatively poor equate to other gynaecologic cancers.5,6,7In the United States for instance , the mortality rate for ovarian genus Cancer declined 33 per centum between 1976 and 2015 , a finding assign to decrease in incidence and improvements in treatment.38

A significant amount of this success can be put down to progress in the number and miscellanea of direction options and biomarker testing.33,35,40,41While the COVID-19 pandemic has reduce rates of biomarker testing and diagnoses,42our increasing understanding of biomarkers is helping to improve the diagnosis and final result of ovarian genus Cancer for a growing number of people.40,43

• This concern to people who were assigned female at birth .

The depicted object of this article is not intended to be a replacement for professional aesculapian advice , diagnosing , or treatment . Always seek the advice of qualified wellness providers with question you may have regarding medical conditions . entropy in this article was correct on the date of publication .

address

1.H. Sung , et al . Global Cancer Statistics 2020 : GLOBOCAN estimate of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries . CA : A Cancer Journal for Clinicians . 2021 ; 71 : 209 - 249 .

2.L. Berben , G. Floris , H. Wildiers & S. Hatse . genus Cancer and Aging : Two Tightly Interconnected Biological Processes . cancer . 2021 ; 13 .

3.Cancer Research UK . Ovarian cancer incidence statistics . Available athttps://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer/incidence .   Accessed March 2023 .

4.J. Lee , et al . Changes in ovarian cancer survival during the 20 years before the epoch of targeted therapy . BMC Cancer . 2018 ; 18 : 601 .

5.B. Reid , J.B. Permuth & T.A. Sellers . Epidemiology of ovarian cancer : a followup . Cancer Biol . Med . 2017 ; 14 : 9–32 .

6.American Cancer Society . Survival Rates for Cervical Cancer . Available athttps://www.cancer.org/cancer/cervical-cancer/detection-diagnosis-staging/survival.html . Accessed March 2023 .

7.Cancer . lucre . Uterine Cancer : Statistics . Available athttps://www.cancer.net/cancer-types/uterine-cancer/statistics . Accessed March 2023 .

8.MedicineNet . Ovarian Cancer : Symptoms & Signs . useable athttps://www.medicinenet.com/ovarian_cancer_symptoms_and_signs/symptoms.htm . Accessed March 2023 .

9.T. P. Hanna , et al . Mortality due to cancer intervention delay : systematic recapitulation and meta - analysis . BMJ . 2020 ; 371 : m4087 .

10.G. Lyratzopoulos et al . rethink diagnostic hold in genus Cancer : how hard is the diagnosing ? BMJ . 2014;349 : G7400 .

11.World Health Organisation . In WHO global pulse rate survey , 90 % of res publica report disruptions to essential health service since COVID-19 pandemic . useable athttps://www.who.int/news/item/2025-01-12-in-who-global-pulse-survey-90-of-countries-report-disruptions-to-essential-health-services-since-covid-19-pandemic . access March 2023 .

12.L. S. Jacome , et al . Impact of COVID-19 Pandemic on Ovarian Cancer Management : Adjusting to the New Normal . Cancer Management and Research . 2021 ; 13 : 359 - 366 .

13.National Cancer Institute . What Is Cancer ? Available athttps://www.cancer.gov/about-cancer/understanding/what-is-cancer . Accessed March 2023 .

14.American Society of Clinical Oncology . What Is Personalized Cancer Medicine ? Available athttps://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/what-personalized-cancer-medicine . Accessed March 2023 .

15.National Cancer Institute . Biomarker Testing for Cancer Treatment . Available athttps://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment . Accessed March 2023 .

16.National Cancer Institute . Definition of Biomarker . uncommitted athttps://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker . Accessed March 2023 .

17.R. Mayeux . Biomarkers : Potential Uses and Limitations . NeuroRX . 2004 ; 1 : 182 - 188 .

18.H.F.M. Kamel & H.S.B Al - Amodi . Cancer Biomarkers , Role of Biomarkers in Medicine , IntechOpen . 2016 ; 50247 .

19.N.L. Henry & D.F. Hayes . Cancer biomarkers . Mol . Oncol . 2012 ; 6 : 140 - 146 .

20.American Society of Clinical Oncology . When the First Treatment Does Not shape . uncommitted athttps://www.cancer.net/navigating-cancer-care/how-cancer-treated/when-first-treatment-does-not-work . get at March 2023 .

21.National Cancer Institute . HRR Pathway . Available athttps://www.cancer.gov/publications/dictionaries/cancer-terms/def/hrr-pathway . access March 2023 .

22.S. Hirsch et al . Germline examination for homologous recombination repair genes — opportunity and challenges . Genes Chromosomes & Cancer . 2020 ; 60 : 332 - 343 .

23.J. Wu , L - Y. Lu & X. Yu . The use of BRCA1 in DNA damage reply . Protein Cell . 2010 ; 1 : 117 - 123 .

24.National Cancer Institute . Tumor Markers in Common Use . Available athttps://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-listAccessed March 2023 .

25.P. Charkhchi , et al . CA125 and Ovarian Cancer : A Comprehensive Review . malignant neoplastic disease . 2020 ; 12 : 3730 .

26.Cancer Research UK . An exist blood test for ovarian cancer has been re - evaluated . The results are in . uncommitted athttps://news.cancerresearchuk.org/2025-03-12/an-existing-blood-test-for-ovarian-cancer-has-been-re-evaluated/. Accessed March 2023 .

27.Mayo Clinic . CA 125 Test . Available athttps://www.mayoclinic.org/tests-procedures/ca-125-test/about/pac-20393295 . access March 2023 .

28.MD Anderson . The University of Texas MD Anderson Cancer Center : CA-125 screening for ovarian cancer may save lifetime . useable athttps://www.mdanderson.org/cancerwise/ca-125-screening-for-ovarian-cancer-may-save-lives.h00-158992968.html . Accessed March 2023 .

29.V. Dochez , et al . Biomarkers and algorithms for diagnosis of ovarian genus Cancer : CA125 , HE4 , RMI and ROMA , a follow-up . Journal of Ovarian Research . 2019 ; 12 : 28 .

30.T. Zhao , et al . CA125 and HE4 : Measurement Tools for Ovarian Cancer . Gynecologic and Obstetric Investigation . 2016 ; 81 : 430 - 5 .

31.L. Janas . Current clinical software of serum biomarkers to detect and monitor ovarian cancer – update . Prz Menopauzalny . 2021 ; 20 : 211–216 .

32.American Cancer Society . oversee Advancer Cancer . Available athttps://www.cancer.org/treatment/understanding-your-diagnosis/advanced-cancer/managing-symptoms.html . access March 2023 .

33.Cancer Research UK . discourse decisions . Available athttps://www.cancerresearchuk.org/about-cancer/ovarian-cancer/treatment/treatment-decisions . access March 2023 .

34.Cancer Research UK . Ovarian Cancer : Chemotherapy treatment . usable athttps://www.cancerresearchuk.org/about-cancer/ovarian-cancer/treatment/chemotherapy/chemotherapy-treatment . access March 2023 .

35.Cancer Treatment Centers of America . Ovarian Cancer Treatment . useable athttps://www.cancercenter.com/cancer-types/ovarian-cancer/treatments . Accessed March 2023 .

36.Z. Dlamini , et al . Artificial intelligence information ( AI ) and big data in cancer and precision oncology . Computational and Structural Biotechnology Journal . 2020 ; 18 : 2300 - 2311 .

37.A. Echle , et al . Deep learning in cancer pathology : a new propagation of clinical biomarkers . British Journal Of Cancer . 2021 ; 124 : 686 - 696 .

38.L. Torre , et al . Ovarian cancer statistics , 2018.CA : A Cancer Journal for Clinicians . 2018 ; 68 : 284 - 296 .

39.Cancer Research UK . Ovarian malignant neoplastic disease selection statistic . uncommitted athttps://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer/survival . Accessed March 2023 .

40.H. J. Whitwell , et al . Improved early detection of ovarian cancer using longitudinal multimarker models . British Journal of Cancer . 2020 ; 122 : 847 - 856 .

41.J. Wu . Improved survival of the fittest in ovarian malignant neoplastic disease , with widening selection gaps of race and socioeconomic status : a geological period analysis , 1983 - 2012 . J Cancer . 2018 ; 9(19 ): 3548 - 3556 .

42.Clinical OMICs . COVID-19 Precipitates Sharp Decline in Cancer Testing , Diagnoses . uncommitted athttps://www.insideprecisionmedicine.com/topics/molecular-dx-topic/molecular-diagnostics-in-vitro-diagnostics/covid-19-precipitates-sharp-decline-in-cancer-testing-diagnoses/. Accessed March 2023 .

43.G. A. Atallah . New Predictive Bimarkers for Ovarian Cancer . Diagnostics ( Basel ) . 2021 ; 11(3 ): 465 .

Document number : Z4 - 39102

Date of preparation : March 2023